Literature DB >> 5349693

Decreased properdin activity in acute glomerulonephritis.

H Gewurz, R J Pickering, G Naff, R Snyderman, S E Mergenhagen, R A Good.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5349693     DOI： 10.1159/000230780

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN： 0020-5915


× No keyword cloud information.
  18 in total

Review 1.  Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis.

Authors:  T Matthew Eison; Bettina H Ault; Deborah P Jones; Russell W Chesney; Robert J Wyatt
Journal:  Pediatr Nephrol       Date:  2010-07-23       Impact factor: 3.714

2.  Role of properdin in kidney diseases.

Authors:  R M Nakamura
Journal:  Calif Med       Date:  1972-05

Review 3.  Complement and the kidney.

Authors:  D K Peters; D G Williams
Journal:  Proc R Soc Med       Date:  1972-12

4.  Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia.

Authors:  N G Westberg; G B Naff; J T Boyer; A F Michael
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

5.  Clinical and immunological studies in a case of selective complete C1q deficiency.

Authors:  A I Berkel; M Loos; O Sanal; G Mauff; Y Güngen; U Ors; F Ersoy; O Yegin
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

6.  Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.

Authors:  B J Potter; D J Brown; A Watson; D P Jewell
Journal:  Gut       Date:  1980-12       Impact factor: 23.059

7.  Complement studies in membrano-proliferative glomerulonephritis.

Authors:  D K Peters; A Martin; A Weinstein; J S Cameron; T M Barratt; C S Ogg; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1972-07       Impact factor: 4.330

8.  Humoral immune system in inflammatory bowel disease: I. Complement levels.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

9.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

10.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.